Steven M Paul

Steven M Paul has an estimated net worth of $171 Million. This is based on reported shares across multiple companies, which include ALNYLAM PHARMACEUTICALS, INC., LILLY ELI & CO, Voyager Therapeutics, Inc., Karuna Therapeutics, Inc., Sage Therapeutics, Inc., SIGMA ALDRICH CORP, Rapport Therapeutics, Inc., and Seaport Therapeutics, Inc..

2019 was Steven M Paul's most active year for acquiring shares with 11 total transactions. Steven M Paul's most active month to acquire stocks was the month of May. 2019 was Steven M Paul's most active year for disposing of shares, totalling 32 transactions. Steven M Paul's most active month to dispose stocks was the month of January. 2024 saw Steven M Paul paying a total of $15,532,273.50 for 173,779 shares, this is the most they've acquired in one year. In 2024 Steven M Paul cashed out on 2,874,864 shares for a total of $829,875,103.59, their largest year based on trade value.